Enamine, Actelion Expand Drug Discovery Collaboration

Enamine Ltd. has expanded its drug discovery collaboration with Actelion Pharmaceuticals to provide library synthesis and medicinal chemistry services for the synthesis of advanced screening compound libraries focused on therapeutic areas including: cardiovascular and central nervous system disorders, immunology, infectious diseases and oncology.
 
The companies have also entered a separate research contract, whereby Enamine will actively support Actelion’s medicinal chemistry efforts. The Enamine database of building blocks has been integrated into Actelion’s IT platform for optimizing the access, ordering and delivery time of any structure necessary for Actelion’s global research projects.
 
Christoph Boss, senior director, Chemistry Technologies and Lead Discovery at Actelion, said, “Enamine is very well positioned among chemical CRO’s. Their screening compound libraries have always been highly regarded in hit-finding projects at Actelion because of their diversity and quality. The combination of Enamine’s large library of building blocks, their synthesis skills and technologies, as well as the excellent level of trust we have built over the years, makes the collaboration very attractive for Actelion. We are happy to be extending our collaboration and I look forward to reaching our next milestones.”
 
Michael Bossert, head of Strategic Alliances at Enamine, said, “We have worked extensively with Actelion over the years, and we are delighted to be entering into further new areas of collaboration with such a leading pharmaceutical company. We see this as another example of Enamine’s technical and servicing expertise for optimizing and advancing our customer’s early discovery research projects. This announcement is the conclusion of another year of great successes and achievements at Enamine, ultimately working toward the launch of life changing medicines by its customers.”